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Almost all cellular processes entail the precise interactions of
proteins that self-assemble either transiently or permanently as
obligate multimers. Unlike native complexes, some proteins as-
semble erroneously, resulting in amyloid fibrils that form insoluble
plaques known to be associated with neurodegenerative diseases,
e.g., Alzheimer’s disease, Parkinson’s disease, bovine spongiform
encephalopathy, and other prion diseases. Due to the prevalence
of fibrils in these diseases, much attention has been given in recent
years to development of inhibitors of protein-based fibril formation.
For example, small-molecule inhibitors of transthyretin fibrillation
have been designed,1 the antibiotic rifampicin causes fibril disas-
sembly in vitro,2 and C-reactive protein has been shown to break
down amyloid deposits in the body.3 In addition, Dumoulin et al.
recently developed a camelid antibody that inhibits fibrillation of
lysozyme.4
Previously we engineered a de novo protein interface by first
docking the normally monomeric â1 domain of Streptococcal
protein-G to itself and then mutating specific interfacial side chains
so as to drive complex formation.5 This design resulted in a pair
of protein monomers that formed a heterodimer of modest binding
affinity. Introduction of the specific mutations that resulted in the
unique sequences of each monomer (referred to as monomer-A and
monomer-B) altered their thermodynamic properties relative to the
wild-type protein-G. The 12 mutations that resulted in the mono-
mer-A sequence stabilized it to a hyperthermophile (i.e., Tm > 100
°C), while the 8 for monomer-B were destabilizing, resulting in a
Tm of 37 °C. The Tm for WT protein-G is 83 °C.
At the concentrations required for NMR studies, monomer-B
alone was observed to form macroscopic fibers (Figure 1). Although
interesting, this in itself is not unusual since many proteins, upon
destabilization, can be induced to form fibers.6-11 The distinctive
aspect of this system is that, in the presence of an equimolar quantity
of monomer-A, no monomer-B fibers were observed. Thus, this
engineered complex proved to be an excellent model system for
studying protein-based fibril inhibition. Here we report the amyloid-
like properties of the monomer-B fibrils and the ability of the
monomer-A binding partner to completely block formation of
monomer-B fibrils.
The physical features and chemical characteristics of amyloid
fibrils were elucidated as early as 1959, when it was determined
using electron microscopy that amyloid plaques do not consist of
amorphous aggregates but instead are made up of microscopic
fibrils. The fibrils are consistently long, straight, and unbranched
with a diameter of 10 nm.12 All amyloid fibrils exhibit cross-â
fibril diffraction and consist of the same structure that contains a
â-sheet oriented perpendicular to the axis of the fibril.13 They also
cause a significant shift and marked increase in the fluorescence
of the dye Thioflavin T (ThT).14 Transmission electron microscopy
(TEM) and ThT fluorescence were used to characterize the amyloid-
like properties of the monomer-B fibrils and to confirm the
inhibitory properties of the binding partner monomer-A.
Monomer-B fibrils were subjected to TEM imaging to confirm
that the fibrils formed were indeed amyloid-like. The micrograph
reveals that monomer-B forms long unbranched fibrils with a
diameter of approximately 10 nm (Figure 2). These parameters are
consistent with the morphology of amyloid type fibrils.15
To quantify the amount of fibrils formed, the fluorescent dye
ThT was utilized. The ThT fluorescence signal shows a large shift
and increase upon binding to â-sheet-containing fibrils.14 To fully
characterize the inhibitory properties of monomer-A, it was
necessary to achieve consistent fibrillation of monomer-B. Monomer-
B, at concentrations used for NMR analysis (i.e., 1.25 mM), was
incubated at four temperatures: 4, 18, 25, and 37 °C. Fibrils were
visible in the 25 and 37 °C samples after 5-7 days. No fibrils
were observed at the other temperatures.
Agitation at the Tm of a protein has been used in fibril formation
studies as it shortens the time required for fibrillation.16 Ramirez-
Alvarado et al. demonstrated that agitation and incubation at the
Tm of a number of protein-G mutant variants shortened the onset
of fibrillation.8 Samples were incubated at 25 and 37 °C and were
agitated and observed visually. After 3 days, more fibrils were
observed in the 37 °C sample; therefore, all subsequent experiments
were performed at 37 °C with agitation.
In addition to agitation, it has also been shown that incubation
with seed fibrils hastens the onset and consistency of fibril
formation.8,17 To normalize seed fibrils added to the fibril formation
solutions, 1.25 mM concentrations of preformed monomer-B fibrils
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Figure 1. Macroscopic fibers were observed to form spontaneously after
approximately 3 days in an NMR tube that contained free monomer-B.
Figure 2. Transmission electron micrograph of monomer-B fibrils.
Although densely packed, the individual microscopic fibrils are unbranched
and of indeterminate length. The diameter of the fibrils is approximately
10 nm.
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were sonicated with three 10-s pulses in a water bath sonicator.
Dilutions of 1:100, 1:1000, and 1:10000 of the sonicated seed fibrils
were used in the onset of fibrillation analysis. Fibril induction was
run in triplicate on 0.6 mM monomer-B solutions. On the basis of
the results, it was determined that the 1:1000-fold dilution was most
consistent in the onset of fibril formation, and therefore both
sonicated and unsonicated 1:1000-fold dilution of seed fibrils were
used for the inhibition assays.
To study the inhibitory effect of monomer-A on monomer-B
fibril formation, triplicate solutions of equimolar quantities (i.e.,
0.6 mM) of the two binding partners were incubated at 37 °C with
agitation and in the presence of seed fibrils for approximately 9
days (Figure 3). In both cases, the ThT fluorescence did not increase
and therefore confirmed that the presence of monomer-A completely
blocked the ability of monomer-B to form fibrils. As a positive
control, monomer-B alone was incubated as above in the presence
of both sonicated and unsonicated 1:1000-fold dilution of seed
fibrils. As predicted, the monomer-B alone samples formed fibrils
and caused a significant increase in ThT fluorescence after only
1.5 days (Figure 3). The samples that received the sonicated fibrils
exhibited a more rapid increase in signal intensity, reflecting an
increase in fibril formation. As a negative control, solutions of 0.6
mM monomer-A alone were incubated at 37 °C with agitation and
also in the presence of preformed monomer-B fibrils under identical
conditions. In both sets of experiments, no fibrils were observed
(data not shown).
To explore the specificity of monomer-A inhibition, equimolar
quantities (i.e., 0.6 mM) of WT protein-G and monomer-B were
incubated under the conditions described above. WT protein-G is
a structural homologue of monomer-A; however, unlike monomer-
A, it was not engineered to interact with monomer-B, and thus
should not inhibit monomer-B fibrillation. As expected, when
monomer-B is agitated in the presence of an equimolar quantity of
WT protein-G, fibril formation is not blocked, yet interestingly,
this solution exhibited a greater increase in ThT fluorescence than
the monomer-B samples alone. Since Ramirez-Alvarado et al. have
demonstrated cross-seeding abilities for some of their protein-G
mutants, we incubated WT protein-G alone with preformed
monomer-B seed fibrils and monitored ThT fluorescence. After
more than 2 weeks, no fibrils were observed. This finding implies
that it is not likely that the increase in fluorescence observed is
due to cross-seeding. Since WT protein-G alone does not form
fibrils at 37 °C, even in the presence of preformed monomer-B
fibrils, its presence may be affecting monomer-B fibril formation
by another mechanism. It has been demonstrated experimentally
that molecular crowding, induced by the addition of high concentra-
tions of different polymers, can dramatically accelerate R-synuclein
fibrillation in vitro.18 If molecular crowding, induced by the
equimolar presence of WT protein-G, is the cause of the increase
in ThT fluorescence, then the ability of monomer-A to completely
block monomer-B fibril formation is of even greater significance,
as it occurs despite a concomitant increase in molecular crowding.
We have demonstrated the ability of a destabilized test protein,
monomer-B, to consistently form amyloid fibrils and, more
importantly, proved that a designed protein interface can effectively
block protein fibril formation. We hypothesize that, in a manner
similar to that observed for the camelid antibody that inhibits
fibrillation of lysozyme,4 monomer-A functions to bind and stabilize
the target fold of monomer-B in the engineered heterodimer.
Complex formation may effectively sequester and stabilize mono-
mer-B and prevent it from sampling folding intermediates that give
rise to self-assembled fibrils. In addition, inhibition by the designed
binding partner is specific in that a structurally homologous variant
(WT protein-G) did not block monomer-B fibril formation and
actually increased ThT fluorescence. Work is underway to apply
these protein design/fibril inhibition techniques to proteins known
to cause disease upon fibrillation. In addition, we are considering
the use of this system to alter the physical characteristics of the
fibrils in an attempt to generate nanostructures of specific geom-
etries.19,20
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Figure 3. ThT fluorescence plotted against incubation time. Monomer-A
blocked monomer-B fibrillation, as confirmed by the fact that no increase
in ThT fluorescence was observed for monomer-B fibrils in the presence
of monomer-A (light and dark pink, flat lines). In contrast, samples of free
monomer-B that received sonicated (dark blue) and unsonicated (lighter
blue) seed fibrils showed a marked increase in ThT fluorescence after
approximately 24 and 48 h, respectively. WT protein-G was incubated with
monomer-B and resulted in an increase in ThT fluorescence (green).
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